Moderna (MRNA) said Friday that it has been awarded a tender to supply its COVID-19 vaccine in the European Union, Norway and North Macedonia.
As a result, 17 participating countries will be able to access the mRNA COVID-19 vaccine for up to four years, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.